1. Home
  2. ADTN vs PBYI Comparison

ADTN vs PBYI Comparison

Compare ADTN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADTRAN Holdings Inc.

ADTN

ADTRAN Holdings Inc.

N/A

Current Price

$6.36

Market Cap

559.8M

ML Signal

N/A

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

N/A

Current Price

$10.15

Market Cap

560.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADTN
PBYI
Founded
1985
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
559.8M
560.1M
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
ADTN
PBYI
Price
$6.36
$10.15
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $14.67
N/A
AVG Volume (30 Days)
★ 1.4M
327.3K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 90.83
N/A
EPS
N/A
★ 0.08
Revenue
★ $1,083,807,000.00
$27,685,000.00
Revenue This Year
$5.74
N/A
Revenue Next Year
$7.88
$1.33
P/E Ratio
★ N/A
$130.50
Revenue Growth
★ 17.46
N/A
52 Week Low
$6.29
$4.58
52 Week High
$19.98
$11.50

Technical Indicators

Market Signals
Indicator
ADTN
PBYI
Relative Strength Index (RSI) 39.78 48.32
Support Level $6.29 $9.04
Resistance Level $7.34 $11.50
Average True Range (ATR) 0.26 0.46
MACD 0.02 -0.07
Stochastic Oscillator 18.71 24.43

Price Performance

Historical Comparison
ADTN
PBYI

About ADTN ADTRAN Holdings Inc.

Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: